APO Research
Talk to an analyst

APO RESEARCH · REPORT

Novel Oral AntiCoagulants (NOAC)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Novel Oral AntiCoagulants (NOAC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025198 pages

Choose your research edition.

Industry ResearchNovel Oral AntiCoagulants (NOAC) Industry Research Report 2026137 pages · $2,950 USDIndustry Growth & TrendsGlobal Novel Oral AntiCoagulants (NOAC) Industry Growth and Trends Forecast to 2032119 pages · $3,450 USDMarket StructureGlobal Novel Oral AntiCoagulants (NOAC) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Novel Oral AntiCoagulants (NOAC) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Novel Oral AntiCoagulants (NOAC) Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Novel Oral AntiCoagulants (NOAC) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Novel Oral AntiCoagulants (NOAC) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Novel Oral AntiCoagulants (NOAC) include Armatheon, Aspen, Boehringer Ingelheim, Bristol-Myers Squibb, Cellceutix, Cosmo Pharmaceuticals, CSL Behring, Daiichi Sankyo and Marathon Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Novel Oral AntiCoagulants (NOAC) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Novel Oral AntiCoagulants (NOAC) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Novel Oral AntiCoagulants (NOAC) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Novel Oral AntiCoagulants (NOAC) market size, projected growth trends, production technologies, key applications, and end-use industries.

Novel Oral AntiCoagulants (NOAC) Segment by Company

Armatheon

Aspen

Boehringer Ingelheim

Bristol-Myers Squibb

Cellceutix

Cosmo Pharmaceuticals

CSL Behring

Daiichi Sankyo

Marathon Pharmaceuticals

Ockham Biotech

Perosphere

AstraZeneca

Bayer

GSK

Johnson & Johnson

Sanofi

Eisai

Novel Oral AntiCoagulants (NOAC) Segment by Type

Direct Thrombin Inhibitors

Direct Factor Xa Inhibitors

Novel Oral AntiCoagulants (NOAC) Segment by Application

Hemodialysis

Deep Vein Thrombosis (DVT)

Acute Coronary Syndrome

Pulmonary Embolism

Others

Novel Oral AntiCoagulants (NOAC) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Oral AntiCoagulants (NOAC) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Novel Oral AntiCoagulants (NOAC) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Oral AntiCoagulants (NOAC).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Novel Oral AntiCoagulants (NOAC) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Novel Oral AntiCoagulants (NOAC) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Novel Oral AntiCoagulants (NOAC) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Novel Oral AntiCoagulants (NOAC) Industry Trends Table 2. Novel Oral AntiCoagulants (NOAC) Industry Drivers Table 3. Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges Table 4. Novel Oral AntiCoagulants (NOAC) Industry Restraints Table 5. Global Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Manufacturers Table 9. Global Novel Oral AntiCoagulants (NOAC) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Novel Oral AntiCoagulants (NOAC) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Novel Oral AntiCoagulants (NOAC) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Novel Oral AntiCoagulants (NOAC) Manufacturers, Product Type & Application Table 13. Global Novel Oral AntiCoagulants (NOAC) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Novel Oral AntiCoagulants (NOAC) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Direct Thrombin Inhibitors Table 17. Major Manufacturers of Direct Factor Xa Inhibitors Table 18. Global Novel Oral AntiCoagulants (NOAC) Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 19. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2026) & (W Units) Table 20. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2027-2032) & (W Units) Table 21. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2021-2026) Table 22. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2027-2032) Table 23. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 24. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2026) & (W Units) Table 25. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2027-2032) & (W Units) Table 26. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2021-2026) Table 27. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hemodialysis Table 29. Major Manufacturers of Deep Vein Thrombosis (DVT) Table 30. Major Manufacturers of Acute Coronary Syndrome Table 31. Major Manufacturers of Pulmonary Embolism Table 32. Major Manufacturers of Others Table 33. Global Novel Oral AntiCoagulants (NOAC) Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 34. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2026) & (W Units) Table 35. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2027-2032) & (W Units) Table 36. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2021-2026) Table 37. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2027-2032) Table 38. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2026) & (W Units) Table 40. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2027-2032) & (W Units) Table 41. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2021-2026) Table 42. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2027-2032) Table 43. Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 44. Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026) & (W Units) Table 45. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Region (2021-2026) Table 46. Global Novel Oral AntiCoagulants (NOAC) Sales Forecasted by Region (2027-2032) & (W Units) Table 47. Global Novel Oral AntiCoagulants (NOAC) Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 49. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 50. North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 51. Europe Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 52. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 53. Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 54. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 55. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 56. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 57. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2026) & (W Units) Table 59. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2027-2032) & (W Units) Table 60. Global Novel Oral AntiCoagulants (NOAC) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2021-2026) Table 64. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2027-2032) Table 65. Armatheon Company Information Table 66. Armatheon Business Overview Table 67. Armatheon Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 69. Armatheon Recent Development Table 70. Aspen Company Information Table 71. Aspen Business Overview Table 72. Aspen Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 74. Aspen Recent Development Table 75. Boehringer Ingelheim Company Information Table 76. Boehringer Ingelheim Business Overview Table 77. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 79. Boehringer Ingelheim Recent Development Table 80. Bristol-Myers Squibb Company Information Table 81. Bristol-Myers Squibb Business Overview Table 82. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 84. Bristol-Myers Squibb Recent Development Table 85. Cellceutix Company Information Table 86. Cellceutix Business Overview Table 87. Cellceutix Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 89. Cellceutix Recent Development Table 90. Cosmo Pharmaceuticals Company Information Table 91. Cosmo Pharmaceuticals Business Overview Table 92. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 94. Cosmo Pharmaceuticals Recent Development Table 95. CSL Behring Company Information Table 96. CSL Behring Business Overview Table 97. CSL Behring Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 99. CSL Behring Recent Development Table 100. Daiichi Sankyo Company Information Table 101. Daiichi Sankyo Business Overview Table 102. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 104. Daiichi Sankyo Recent Development Table 105. Marathon Pharmaceuticals Company Information Table 106. Marathon Pharmaceuticals Business Overview Table 107. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 109. Marathon Pharmaceuticals Recent Development Table 110. Ockham Biotech Company Information Table 111. Ockham Biotech Business Overview Table 112. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 114. Ockham Biotech Recent Development Table 115. Perosphere Company Information Table 116. Perosphere Business Overview Table 117. Perosphere Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 119. Perosphere Recent Development Table 120. AstraZeneca Company Information Table 121. AstraZeneca Business Overview Table 122. AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 124. AstraZeneca Recent Development Table 125. Bayer Company Information Table 126. Bayer Business Overview Table 127. Bayer Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 129. Bayer Recent Development Table 130. GSK Company Information Table 131. GSK Business Overview Table 132. GSK Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 134. GSK Recent Development Table 135. Johnson & Johnson Company Information Table 136. Johnson & Johnson Business Overview Table 137. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 139. Johnson & Johnson Recent Development Table 140. Sanofi Company Information Table 141. Sanofi Business Overview Table 142. Sanofi Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 144. Sanofi Recent Development Table 145. Eisai Company Information Table 146. Eisai Business Overview Table 147. Eisai Novel Oral AntiCoagulants (NOAC) Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio Table 149. Eisai Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Novel Oral AntiCoagulants (NOAC) Distributors List Table 153. Novel Oral AntiCoagulants (NOAC) Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Novel Oral AntiCoagulants (NOAC) Product Image Figure 2. Global Novel Oral AntiCoagulants (NOAC) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Novel Oral AntiCoagulants (NOAC) Market Size (2021-2032) & (US$ Million) Figure 4. Global Novel Oral AntiCoagulants (NOAC) Sales (2021-2032) & (W Units) Figure 5. Global Novel Oral AntiCoagulants (NOAC) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Direct Thrombin Inhibitors Image Figure 9. Direct Factor Xa Inhibitors Image Figure 10. Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 11. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2021-2032) Figure 13. Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2021-2032) Figure 16. Hemodialysis Image Figure 17. Deep Vein Thrombosis (DVT) Image Figure 18. Acute Coronary Syndrome Image Figure 19. Pulmonary Embolism Image Figure 20. Others Image Figure 21. Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 22. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2021-2032) Figure 24. Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 25. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2021-2032) Figure 27. North America Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 28. North America Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2032) Figure 29. U.S. Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 30. Canada Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 31. Mexico Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 32. Europe Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 33. Europe Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2032) Figure 34. Germany Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 35. France Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 36. U.K. Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Italy Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Netherlands Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 39. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 40. Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2032) Figure 41. China Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Japan Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 43. South Korea Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Southeast Asia Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 45. India Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 46. Australia Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 47. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Market Share by Country (2021-2032) Figure 49. Brazil Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 50. South Africa Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Saudi Arabia Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 52. Turkey Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 53. Argentina Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 54. UAE Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 55. Egypt Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Chile Novel Oral AntiCoagulants (NOAC) Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Global Novel Oral AntiCoagulants (NOAC) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Figure 60. North America Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Figure 62. Europe Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Novel Oral AntiCoagulants (NOAC) Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Novel Oral AntiCoagulants (NOAC) Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Direct Thrombin Inhibitors
  • Direct Factor Xa Inhibitors
Applications
  • Hemodialysis
  • Deep Vein Thrombosis (DVT)
  • Acute Coronary Syndrome
  • Pulmonary Embolism
  • Others
Companies covered
  • Armatheon
  • Aspen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cellceutix
  • Cosmo Pharmaceuticals
  • CSL Behring
  • Daiichi Sankyo
  • Marathon Pharmaceuticals
  • Ockham Biotech
  • Perosphere
  • AstraZeneca
  • Bayer
  • GSK
  • Johnson & Johnson
  • Sanofi
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Novel Oral AntiCoagulants (NOAC) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Novel Oral AntiCoagulants (NOAC) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Novel Oral AntiCoagulants (NOAC) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Novel Oral AntiCoagulants (NOAC) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Novel Oral AntiCoagulants (NOAC) Market Dynamics
  1. 2.1 Novel Oral AntiCoagulants (NOAC) Industry Trends
  2. 2.2 Novel Oral AntiCoagulants (NOAC) Industry Drivers
  3. 2.3 Novel Oral AntiCoagulants (NOAC) Industry Opportunities and Challenges
  4. 2.4 Novel Oral AntiCoagulants (NOAC) Industry Restraints
3 Novel Oral AntiCoagulants (NOAC) Market by Manufacturers
  1. 3.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Novel Oral AntiCoagulants (NOAC) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Novel Oral AntiCoagulants (NOAC) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Novel Oral AntiCoagulants (NOAC) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Novel Oral AntiCoagulants (NOAC) Manufacturers, Product Type & Application
  7. 3.7 Global Novel Oral AntiCoagulants (NOAC) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Novel Oral AntiCoagulants (NOAC) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Novel Oral AntiCoagulants (NOAC) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Novel Oral AntiCoagulants (NOAC) Tier 1, Tier 2, and Tier 3
4 Novel Oral AntiCoagulants (NOAC) Market by Type
  1. 4.1 Novel Oral AntiCoagulants (NOAC) Type Introduction
  2. 4.1.1 Direct Thrombin Inhibitors
  3. 4.1.2 Direct Factor Xa Inhibitors
  4. 4.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Type
  5. 4.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Type (2021-2032)
  7. 4.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type
  9. 4.3.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Type (2021-2032)
  11. 4.3.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Type (2021-2032)
5 Novel Oral AntiCoagulants (NOAC) Market by Application
  1. 5.1 Novel Oral AntiCoagulants (NOAC) Application Introduction
  2. 5.1.1 Hemodialysis
  3. 5.1.2 Deep Vein Thrombosis (DVT)
  4. 5.1.3 Acute Coronary Syndrome
  5. 5.1.4 Pulmonary Embolism
  6. 5.1.5 Others
  7. 5.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Application
  8. 5.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Application (2021-2032)
  10. 5.2.3 Global Novel Oral AntiCoagulants (NOAC) Sales Market Share by Application (2021-2032)
  11. 5.3 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application
  12. 5.3.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Application (2021-2032)
  14. 5.3.3 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Application (2021-2032)
6 Global Novel Oral AntiCoagulants (NOAC) Sales by Region
  1. 6.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2032)
  3. 6.2.1 Global Novel Oral AntiCoagulants (NOAC) Sales by Region (2021-2026)
  4. 6.2.2 Global Novel Oral AntiCoagulants (NOAC) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region
  1. 7.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region
  2. 7.1.1 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2021-2026)
  4. 7.1.3 Global Novel Oral AntiCoagulants (NOAC) Revenue by Region (2027-2032)
  5. 7.1.4 Global Novel Oral AntiCoagulants (NOAC) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032)
  8. 7.2.2 North America Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032)
  11. 7.3.2 Europe Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Novel Oral AntiCoagulants (NOAC) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Armatheon
  2. 8.1.1 Armatheon Company Information
  3. 8.1.2 Armatheon Business Overview
  4. 8.1.3 Armatheon Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Armatheon Novel Oral AntiCoagulants (NOAC) Product Portfolio
  6. 8.1.5 Armatheon Recent Developments
  7. 8.2 Aspen
  8. 8.2.1 Aspen Company Information
  9. 8.2.2 Aspen Business Overview
  10. 8.2.3 Aspen Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Aspen Novel Oral AntiCoagulants (NOAC) Product Portfolio
  12. 8.2.5 Aspen Recent Developments
  13. 8.3 Boehringer Ingelheim
  14. 8.3.1 Boehringer Ingelheim Company Information
  15. 8.3.2 Boehringer Ingelheim Business Overview
  16. 8.3.3 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Boehringer Ingelheim Novel Oral AntiCoagulants (NOAC) Product Portfolio
  18. 8.3.5 Boehringer Ingelheim Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Novel Oral AntiCoagulants (NOAC) Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Cellceutix
  26. 8.5.1 Cellceutix Company Information
  27. 8.5.2 Cellceutix Business Overview
  28. 8.5.3 Cellceutix Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Cellceutix Novel Oral AntiCoagulants (NOAC) Product Portfolio
  30. 8.5.5 Cellceutix Recent Developments
  31. 8.6 Cosmo Pharmaceuticals
  32. 8.6.1 Cosmo Pharmaceuticals Company Information
  33. 8.6.2 Cosmo Pharmaceuticals Business Overview
  34. 8.6.3 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Cosmo Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  36. 8.6.5 Cosmo Pharmaceuticals Recent Developments
  37. 8.7 CSL Behring
  38. 8.7.1 CSL Behring Company Information
  39. 8.7.2 CSL Behring Business Overview
  40. 8.7.3 CSL Behring Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 CSL Behring Novel Oral AntiCoagulants (NOAC) Product Portfolio
  42. 8.7.5 CSL Behring Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo Novel Oral AntiCoagulants (NOAC) Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 Marathon Pharmaceuticals
  50. 8.9.1 Marathon Pharmaceuticals Company Information
  51. 8.9.2 Marathon Pharmaceuticals Business Overview
  52. 8.9.3 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Marathon Pharmaceuticals Novel Oral AntiCoagulants (NOAC) Product Portfolio
  54. 8.9.5 Marathon Pharmaceuticals Recent Developments
  55. 8.10 Ockham Biotech
  56. 8.10.1 Ockham Biotech Company Information
  57. 8.10.2 Ockham Biotech Business Overview
  58. 8.10.3 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Ockham Biotech Novel Oral AntiCoagulants (NOAC) Product Portfolio
  60. 8.10.5 Ockham Biotech Recent Developments
  61. 8.11 Perosphere
  62. 8.11.1 Perosphere Company Information
  63. 8.11.2 Perosphere Business Overview
  64. 8.11.3 Perosphere Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Perosphere Novel Oral AntiCoagulants (NOAC) Product Portfolio
  66. 8.11.5 Perosphere Recent Developments
  67. 8.12 AstraZeneca
  68. 8.12.1 AstraZeneca Company Information
  69. 8.12.2 AstraZeneca Business Overview
  70. 8.12.3 AstraZeneca Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AstraZeneca Novel Oral AntiCoagulants (NOAC) Product Portfolio
  72. 8.12.5 AstraZeneca Recent Developments
  73. 8.13 Bayer
  74. 8.13.1 Bayer Company Information
  75. 8.13.2 Bayer Business Overview
  76. 8.13.3 Bayer Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bayer Novel Oral AntiCoagulants (NOAC) Product Portfolio
  78. 8.13.5 Bayer Recent Developments
  79. 8.14 GSK
  80. 8.14.1 GSK Company Information
  81. 8.14.2 GSK Business Overview
  82. 8.14.3 GSK Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 GSK Novel Oral AntiCoagulants (NOAC) Product Portfolio
  84. 8.14.5 GSK Recent Developments
  85. 8.15 Johnson & Johnson
  86. 8.15.1 Johnson & Johnson Company Information
  87. 8.15.2 Johnson & Johnson Business Overview
  88. 8.15.3 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Johnson & Johnson Novel Oral AntiCoagulants (NOAC) Product Portfolio
  90. 8.15.5 Johnson & Johnson Recent Developments
  91. 8.16 Sanofi
  92. 8.16.1 Sanofi Company Information
  93. 8.16.2 Sanofi Business Overview
  94. 8.16.3 Sanofi Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Sanofi Novel Oral AntiCoagulants (NOAC) Product Portfolio
  96. 8.16.5 Sanofi Recent Developments
  97. 8.17 Eisai
  98. 8.17.1 Eisai Company Information
  99. 8.17.2 Eisai Business Overview
  100. 8.17.3 Eisai Novel Oral AntiCoagulants (NOAC) Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Eisai Novel Oral AntiCoagulants (NOAC) Product Portfolio
  102. 8.17.5 Eisai Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Novel Oral AntiCoagulants (NOAC) Value Chain Analysis
  2. 9.1.1 Novel Oral AntiCoagulants (NOAC) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Novel Oral AntiCoagulants (NOAC) Production Mode & Process
  6. 9.2 Novel Oral AntiCoagulants (NOAC) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Novel Oral AntiCoagulants (NOAC) Distributors
  9. 9.2.3 Novel Oral AntiCoagulants (NOAC) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst